News Releases
All Releases
View Summary Avid Bioservices to Highlight Recent Successes in Reducing Manufacturing Costs and Novel Ways of Controlling Critical Process Parameters That Lead to Consistent Product Quality at IBC'S Biopharmaceutical Development and Production Conference
Feb 26, 2013
PDF 18.7 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Updates Top-Line Data From Phase II Clinical Trial of Bavituximab in Second-Line Non-Small Cell Lung Cancer
Feb 19, 2013
PDF 20.0 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Announces Results From Phase II Clinical Trial of Bavituximab in Stage IV Pancreatic Cancer
Feb 13, 2013
PDF 17.1 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Provides Update on the Internal Review of Its Phase II Second-Line Non-Small Cell Lung Cancer Trial
Jan 7, 2013
PDF 17.7 KB Add to Briefcase
View Summary Peregrine Regains Compliance With NASDAQ Minimum Bid Price Listing Requirement
Dec 11, 2012
PDF 14.0 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Reports Second Quarter Fiscal Year 2013 Financial Results and Recent Developments
Dec 10, 2012
PDF 29.9 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Announces Significant Progress in Advancing Its Cotara Program Into a Pivotal Phase III Trial
Dec 5, 2012
PDF 18.7 KB Add to Briefcase
View Summary Peregrine to Report Second Quarter Fiscal Year 2013 Financial Results After Market Close on December 10, 2012
Dec 3, 2012
PDF 14.8 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Announces Receipt of Notice From NASDAQ
Nov 14, 2012
PDF 13.4 KB Add to Briefcase
View Summary New Data Support Ability of PS-Targeting Antibodies to Specifically Target Tumors and Stimulate Cancer-Fighting Immune Responses
Oct 31, 2012
PDF 20.0 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Provides Update on Corporate Activities
Oct 17, 2012
PDF 21.5 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Announces New Location of Annual Meeting of Stockholders
Sep 27, 2012
PDF 13.3 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Announces That It Has Discovered Major Discrepancies in Treatment Group Coding by an Independent Third-Party Vendor Responsible for Distribution of Blinded Investigational Product Used in Its Bavituximab Phase II Second-Line Non-Small Cell Lung Cancer Trial
Sep 24, 2012
PDF 15.9 KB Add to Briefcase
View Summary Peregrine to Participate in Credit Suisse 2012 Small & Mid Cap Conference on September 21, 2012
Sep 12, 2012
PDF 13.3 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Reports First Quarter Fiscal Year 2013 Financial Results and Recent Developments
Sep 10, 2012
PDF 27.6 KB Add to Briefcase
View Summary Interim Data From Peregrine's Phase II Trial in Second-Line Non-Small Cell Lung Cancer Demonstrate Doubling of Median Overall Survival in Bavituximab-Containing Arms
Sep 7, 2012
PDF 23.3 KB Add to Briefcase
View Summary Peregrine to Report First Quarter Fiscal Year 2013 Financial Results Before Market on September 10, 2012
Sep 4, 2012
PDF 14.9 KB Add to Briefcase
View Summary Data From Peregrine's Phase II Bavituximab Second-Line Lung Cancer Trial to Be Highlighted in Late-Breaking Oral Presentation at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology
Sep 4, 2012
PDF 17.5 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Secures $30 Million Loan Facility
Aug 30, 2012
PDF 19.6 KB Add to Briefcase
View Summary Peregrine to Present at Stifel Nicolaus Healthcare Conference September 5, 2012 at 2:40 PM EDT
Aug 29, 2012
PDF 14.5 KB Add to Briefcase
Showing 21-40 of 515 Page: 1 2 3 4 5 6 ... 26 Previous 20 | Next 20
Add to Briefcase = add release to Briefcase
Print E-mail